Switching from intermittently scanned to real-time continuous glucose monitoring for diabetes management
Effect of Switching From Intermittently Scanned Continuous Glucose Monitoring to Real-time Continuous Glucose Monitoring on Glycemic Outcomes in Adults With Type 2 Diabetes
This study is testing if switching from a type of glucose monitor that you check occasionally to one that gives real-time readings helps adults with insulin-treated type 2 diabetes manage their blood sugar better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | LMC Diabetes & Endocrinology Ltd. Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06805786 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the impact of switching from intermittently scanned continuous glucose monitoring (isCGM) to real-time continuous glucose monitoring (rtCGM) on diabetes management in adults with insulin-treated type 2 diabetes. Participants will be followed for 3-6 months to assess changes in time in range (TIR) and other glycemic outcomes. The study compares outcomes between those who switch to rtCGM and those who continue using isCGM. It is conducted in a specialist endocrinology clinic in Canada.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a clinical diagnosis of type 2 diabetes who have been using insulin for at least 6 months and currently using a FreeStyle Libre® 2 isCGM device.
Not a fit: Patients who have used real-time continuous glucose monitoring within the past 12 months or are expecting changes in their antihyperglycemic medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve diabetes management and glycemic control for patients using continuous glucose monitoring.
How similar studies have performed: Other studies have shown positive outcomes with continuous glucose monitoring approaches, suggesting potential success for this study as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older * Clinical diagnosis of T2D ≥ one year * Using insulin for ≥ 6 months * Continued FreeStyle Libre® 2 isCGM device (isCGM cohort) as of the study start date * Would like to switch from a FreeStyle Libre® 2 isCGM device to a Dexcom® G7 rtCGM device (rtCGM switch cohort) as of the study start date * Baseline HbA1c ≥ 7.5% * Known rtCGM/isCGM start date (month and year) * Exclusive use of isCGM for ≥ 3 months * Data on LibreView platforms have percent sensor capture ≥ 70% for 14 days of available data up to 6 months prior to index date * ≥ 1 value for TIR (%) up to 6 months (± 6 weeks) prior to index date * ≥ 1 value for HbA1c (%) up to 6 months (± 6 weeks) prior to index date * Data consent Exclusion Criteria: * Have a prior history of rtCGM within 12 months of the index date * Recent or expectant change to antihyperglycemic medications or doses within 30 days of index date * Recent or expectant titration of insulin dose ≥ 20% within 30 days of index date * Are pregnant at the time of study enrollment or intending to become pregnant during the study * Used the isCGM or rtCGM for \< 3 months * Using continuous subcutaneous insulin infusion
Where this trial is running
Toronto, Ontario
- LMC Diabetes & Endocrinology Ltd. — Toronto, Ontario, Canada (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.